A study of variability in glycaemia in children and adolescents with diabetes mellitus type 1 on treatment with insulin glargine;Estudio de la variabilidad glucémica en niños y adolescentes con diabetes tipo 1 en tratamiento con insulina glargina

Anales de Pediatria

Volumn 69, Issue 5, 2008, Pages 426-431

  Rodriguez Perez C ^a,b   Lizondo Escuder, A ^a   Lopez Garcia M J ^a   Escriva Cholbi L ^a   Alpera Lacruz, R ^a   Collado Perez C ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b NONE   (Spain)

Author keywords

Children; Hyperglycaemia; Hypoglycaemia; Insulin glargine; Type 1 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE;

ADOLESCENT; ADULT; ARTICLE; BODY MASS; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MORNING DOSAGE; PROSPECTIVE STUDY; QUALITY OF LIFE; RETROSPECTIVE STUDY;

EID: 55949128284     PISSN: 16954033     EISSN: 16959531     Source Type: Journal    
DOI: 10.1157/13127997     Document Type: Article

References (22)

1. Dahl-Jorgensen K. Modern insulin therapy in children and adolescents. Acta Paediatr Suppl. 1999;88:25-30.
2. Barrio R, Gussinyé M, Hermoso F, González I, Gómez A, López MJ, et al, Comisión de Diabetes Infantil de la Sociedad Española de Endocrinología Pediátrica. Insulinoterapia 2006: Tratamiento en el niño y adolescente. Madrid: Laboratorios Lilly; 2006.
3. Dunger DB. Diabetes in puberty. Arch Dis Child. 1992;67:569-70.
4. Becker DJ, Ryan CM. Hypoglycemia: a complication of diabetes therapy in children. Trends Endocrinol Metab. 2000;11:198-202.
5. Tan CY, Wilson DM, Buckingham B. Initation of insulin glargine in children and adolescents with type 1 diabetes. Pediatr Diabetes. 2004;5:80-6.
6. Chase HP, Dixon B, Pearson J, Fiallo-Scharer R, Walnavens P, Kligensmith G, et al. Reduced hypoglucemic episodes and improved glycemic control in children with type 1 diabetes using insulin glargine and neutral protamin Hagedorn insulin. J Pediatr. 2003;143:737-40.
7. Hathout EH, Fujishige L, Geach J, Ischandar M, Mauro S, Mace JW. Effect of therapy with insulin glargine (lantus) on glycemic control in toddlers, children, and adolescents with diabetes. Diabetes Technol Ther. 2003;5:801-6.
8. Ratner RE, Hirsch IB, Neiging JL, Garg SK, Mecca TE, Wilson CA. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care. 2000;23:639-43.
9. Heinemann L, Linkeschova R, Rove K, Hompesch B, Sedlak M, Heise T. Time Action Profile of the long-acting insulin analog insuline glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care. 2000;23:644-9.
10. Rosenstock J, Park G, Zimmerman J; US IG (HOE901) Type 1 Diabetes Investigator Group. Basal insulin glargine (HOE 901) versus NPH insulin patients with type 1 diabetes on multiple daily insulin regimens. Diabetes Care. 2000;23:1137-42.
11. Danne T, Lupke K, Walte K, Von Schuetz W, Gall MA. Levemir is characterised by a consistent pharmacokinetic profile across age groups in children, adolescents and adults with type 1 diabetes. Diabetes Care. 2003;26:3087-92.
12. Heise T, Nosek L, Ronn BB, Endahl L, Heinemann L, Kapitza C, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes Care. 2004;53:1614-20.
13. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-86.
14. ISPAD Consensus Guidelines for the Management of Type 1 Diabetes Mellitus in Children and Adolescents 2000. Disponible en: http://www.diabetesguidelines. com/health/dwk/pro/guidelines/ispad/ispad.asp
15. American Diabetes Association. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care. 2002;12:303-9.
16. American Diabetes Association. Diabetes mellitus and exercise. Diabetes Care. 2002;25 Suppl 1:64-8.
17. Schober E, Schoenle E, Van Dyk J, Wernicke-Paten K; Pediatric Study Group of Insulin Glargine. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2002;15:369-76.
18. Colino E, López-Capapé M, Golmayo L, Álvarez MA, Alonso M, Barrio R. Therapy with insulin glargine (Lantus) in toddlers, children and adolescents with type 1 diabetes. Diabetes Res Clin Pract. 2005;70:1-7.
19. Jackson A, Ternand C, Brunzell C, Kleinschmidt T, Dew D, Milla C, et al. Insulin glargine improves haemoglobin A1c in children and adolescents with poorly controlled type 1 diabetes. Pediatr Diabetes. 2003;4:64-9.
20. Hamann A, Matthaei S, Rosak C, Silvestre L; HOE901/4007 Study Group. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes. Diabetes Care. 2003;26:1738-44.
21. Alemzadeh R, Berhe T, Wyatt DT. Flexible insulin therapy with glargine insulin improved glycemic control and reduced severe hypoglycemia among preschool-aged children with type 1 diabetes mellitus. Pediatrics. 2005;115:1320-4.
22. Dixon B, Chase HP, Burdick J, Fiallo-Scharer R, Walnavens P, Kligensmith G, et al. Use insulin glargine in children under age 6 with type 1 diabetes. Pediatr Diabetes. 2005;6:150-4.